ETH47

Phase 2Small molecule

EEthris GmbH

ETH47 is one of 20 small molecule programs targeting Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaActive, not recruiting

Asthma (diagnosis)Recruiting

AsthmaPhase 2

Active, not recruiting

Asthma (diagnosis)Phase 2

Recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 2

Spiriva

Boehringer Ingelheim

Preclinical

8 3

Atrovent

Boehringer Ingelheim

Preclinical

5 4

Formoterol Fumarate

AstraZeneca

Preclinical

8 5

ETH47

EEthris GmbH

Phase 2

2 6

Atrovent

Boehringer Ingelheim

Preclinical

2 7

Aciphex

Akero Therapeutics

Preclinical

2 8

Tylenol

KKenvue Brands

Preclinical

1 9

Paracetamol

GSK

Preclinical

1 10

Aclidinium Bromide

AstraZeneca

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Single Ascending Dose1 trial

A Phase 1, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of ETH47 in Healthy Participants

Completed·EEthris GmbH·Phase 1·NCT07055321·73 enrolled

Asthma (Diagnosis)1 trial

A Phase IIa, Double-blind, Randomized, Placebo-controlled Trial in Participants With Asthma to Evaluate the Impact of Intranasal ETH47 on the Development of Asthma-related Symptoms Following Rhinovirus Challenge

Recruiting·EEthris GmbH·Phase 2·NCT07059767·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ETH47. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ETH47 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ETH47. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ethris GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEthris GmbH

ETH47

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Single Ascending Dose1 trial

Asthma (Diagnosis)1 trial

References

Drug Info

Quick Facts

Related News